Rybrevant (amivantamab-vmjw), Rybrevant Faspro (amivantamab and hyaluronidase-lpuj)
Customize your policy alerts
Sign up for Empire Bluecross Policy CC-0201 alerts
Get alerted when Policy CC-0201 changes without checking for updates manually.
Monitor payer policy activity
This policy governs medical-necessity and prior-authorization coverage for amivantamab-vmjw and amivantamab/hyaluronidase-lpuj in adults with specified EGFR-mutated non-small cell lung cancer, including selected brain and leptomeningeal metastases. It applies to requests reviewed under the member's medical benefit.
The policy added an NCCN 2A indication for NSCLC-related leptomeningeal metastases in EGFR exon 19 deletion or exon 21 L858R substitution mutation-positive disease treated with lazertinib.
ICD-10-CM code C79.32 for secondary malignant neoplasm of cerebral meninges was added to the coding section.
The policy revised the coding for Rybrevant Faspro by removing HCPCS C9999 and J9999 effective June 30, 2026, and adding HCPCS J9062 effective July 1, 2026.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.